

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

EL 398889618 US

April 8, 2004

USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Service's Express Mail Post Office to Addressee service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1710, Alexandria, VA 22313-1450.

By:

Sarah M. Barnett

OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06843.0067-02000	Appln. No.	09/187,693
Applicant	Aya JAKOBOVITS et al.	Conf. No.	3392
Filing Date	November 5, 1998	Group:	1644

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
712 863 A1	May 22, 1996	EPO			
586 002 A2	Aug 18, 1993	EPO			
WO 96/34096 A	Oct 31, 1996	PCT			
WO 96/40210 A	Dec 19, 1996	PCT			
WO 98/24893 A	Jun 11, 1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

J. Corvalan et al., January 1, 1997, "Generation of fully human high affinity monoclonal antibodies to EGF receptor in mice," The Journal of Allergy and Clinical Immunology, 99(1, part 2, supp.): s15.
GenBank Accession Number Z70619, <i>H. sapiens</i> mRNA for immunoglobulin heavy chain variable regions (6D4-A5, VH4, 4-31/DP-65), accessed December 3, 1998 (1996).
GenBank Accession Number Z70658, <i>H. sapiens</i> mRNA for immunoglobulin heavy chain variable regions (83-6H3, VH4, 4-61/DP-66), accessed December 3, 1998 (1996).
A. Jakobovits et al., January, 1997, "Humoral immunity in mice engineered with megabase human heavy and kappa light chain YACs," The Journal of Allergy and Clinical Immunology, 99(1, part 2, supp.): s113.
A. Jakobovits et al., April 6, 1998, "Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci," Advanced Drug Delivery Reviews, 31(1-2): 33-42.
A. Jakobovits, April 1998, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," Expert Opinion on Investigational Drugs, 7(4): 607-614.
J. Klein, 1982, <i>Immunology: The Science of Self-Nonself Discrimination</i> , John Wiley & Sons: New York, NY p. 176-183.

6/3/04

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

EL 398889618 US

April 8, 2004

USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Sarah M. Barnett

OMB No. 0651-0011

APR 8 2004

INFORMATION DISCLOSURE CITATION

Atty. Docket No. <u>06843-0067-02000</u>	Appln. No. <u>09/187,693</u>
Applicant <u>Aya JAKOBOVITS et al.</u>	Conf. No. <u>3392</u>
Filing Date <u>November 5, 1998</u>	Group: <u>1644</u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<u>PSA</u>	T. Matsumoto et al., March 1997, "Chimeric monoclonal antibody (Mab) C225 to the epidermal growth factor receptor (EGF-R) inhibits the growth of human transitional cell carcinoma (TCC) in the bladder of nude mice," <u>Proceedings of the American Association for Cancer Research</u> , 38: 229.
<u>1</u>	M. Mendez et al., February 1997, "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <u>Nature Genetics</u> , 15: 146-156.
<u>1</u>	H. Modjtahedi et al., 1994, "The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review)," <u>International Journal of Oncology</u> 4:277-296.
<u>1</u>	G. Schulz et al., 1979, <u>Principles of Protein Structure</u> , Springer-Verlag: New York, NY, pp. 14-16.
<u>1</u>	International Search Report for PCT Application No. PCT/US98/09160.

Examiner <u>DE J. X</u>	Date Considered <u>6/3/04</u>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce